Loading clinical trials...
Loading clinical trials...
Randomized, Ph3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Vs Treatment of Physician's Choice in Patients With Advanced Melanoma That Progressed on Anti-PD-1 and Anti-CTLA-4 Containing Treatment [IGNYTE-3]
Conditions
Interventions
Vusolimogene Oderparepvec
Nivolumab
+3 more
Locations
73
United States
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States
UC San Diego Moores Cancer Center
La Jolla, California, United States
The Angeles Clinic and Research Institute
Los Angeles, California, United States
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States
UCLA Department of Medicine - Hematology/Oncology
Los Angeles, California, United States
UC Irvine Health, Chao Family Comprehensive Cancer Center
Orange, California, United States
Start Date
July 11, 2024
Primary Completion Date
January 1, 2029
Completion Date
August 31, 2034
Last Updated
March 13, 2026
NCT05969860
NCT05039801
NCT06066138
NCT07310784
NCT06214156
NCT06472661
Lead Sponsor
Replimune, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions